Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

NCT01664182 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

NIH

Sponsor class

Conditions

Advanced Renal Cell Carcinoma
Advanced Sarcomatoid Renal Cell Carcinoma
Stage III Renal Cell Cancer AJCC v7
Stage IV Renal Cell Cancer AJCC v7

Interventions

BIOLOGICAL: Bevacizumab
DRUG: Pazopanib Hydrochloride
DRUG: Sorafenib Tosylate
DRUG: Sunitinib Malate
BIOLOGICAL: Trebananib

Sponsor

National Cancer Institute (NCI)